Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US9616015B2 · kind B2 · utility
2Cited by
92References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 11, 2015 |
| Grant date | Apr 11, 2017 |
| Priority date | — |
| Expiry date | Jun 11, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are high concentration compositions of tissue kallikrein-1 (KLK1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human KLK1 (rhKLK1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.